Although the RAR agonist Palovarotene is undergoing clinical trials for FOP, further pre-clinical animal studies will be required to investigate its efficacy and safety for the post-traumatic HO indication. The gene discussed is RARA; the disease is fibrodysplasia ossificans progressiva.